Related Experiment Videos
Insights
Bacteremia in febrile children can resolve naturally, but some require treatment. Early intervention with antibiotics is recommended for high-risk infants to prevent persistent illness.
Area of Science:
- Pediatrics
- Infectious Diseases
- Microbiology
Background:
- Bacteremia is common in young febrile children, often linked to specific risk factors.
- While some cases resolve without antibiotics, many untreated children experience persistent disease.
Purpose of the Study:
- To review risk factors, diagnostic value, and treatment controversies for pediatric bacteremia.
- To provide a clinical judgment on presumptive antibiotic therapy for at-risk children.
Main Methods:
- Review of existing data from randomized trials on bacteremia treatment.
- Clinical judgment based on risk factors such as age, fever, and white blood cell count.
Main Results:
- Risk factors for bacteremia include age (6-24 months), high fever, and elevated white blood cell count or erythrocyte sedimentation rate.
- Blood cultures are valuable for diagnosis, with potential future enhancements through antigen detection methods.
Conclusions:
- Presumptive antibiotic therapy is warranted for children aged 6-24 months with high fever and high white blood cell count.
- Recommended therapies include amoxicillin, trimethoprim-sulfamethoxazole, or cefaclor, targeting common pathogens like Streptococcus pneumoniae and Haemophilus influenzae.
Abstract:
Bacteremia is a relatively common event in young, apparently mildly ill febrile children. The bacteremia is associated with certain risk factors including age, elevated temperature and high white blood cell count or increased erythrocyte sedimentation rate. The disease and bacteremia clears without antimicrobial agents in some children, but many untreated children have persistent disease. Culture of blood is valuable in children with risk features and may be enhanced in the future as methods for detection of antigen become more widely available. Available data from randomized trials of therapy do not provide clear guidelines for treatment and opinions about optimal management of children at risk for bacteremia vary. My judgement is that presumptive therapy is warranted for the child who is 6 to 24 months of age, who has high fever and has high white blood cell count. Therapy should be effective for the pneumococcus and for H. influenzae. Currently, I recommend amoxicillin or, for children allergic to penicillin, trimethoprim-sulfamethoxazole or cefaclor. After 48 to 72 hours the physician can judge the clinical course and will have data from cultures to base decisions about management of the illness.